Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 19/20 | 0.45 |
| ▸ | ITGA4 | P13612 | 19/20 | 0.45 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6167757 | 1.00 | ITGB1 (0.45) | ITGB1ITGA4ITGB7 | |
| SCHEMBL6164569 | 0.99 | ITGB1 (0.46) | ITGB1ITGA4ITGB7 | |
| SCHEMBL6164563 | 0.99 | ITGB1 (0.46) | ITGB1ITGA4ITGB7 | |
| SCHEMBL6167769 | 0.99 | ITGB1 (0.45) | ITGB1ITGA4ITGB7 | |
| SCHEMBL6167758 | 0.94 | ITGA4 (0.41) | ITGB1ITGA4 | |
| SCHEMBL6165075 | 0.92 | ITGA4 (0.46) | ITGB1ITGA4 | |
| SCHEMBL6165081 | 0.92 | ITGA4 (0.46) | ITGB1ITGA4 | |
| SCHEMBL6166829 | 0.91 | ITGA4 (0.43) | ITGB1ITGA4ITGB7 | |
| SCHEMBL6166820 | 0.91 | ITGA4 (0.43) | ITGB1ITGA4ITGB7 | |
| SCHEMBL5195038 | 0.90 | ITGA4 (0.43) | ITGB1ITGA4ITGB7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1373249-B1 | IMIDAZOLIDINE DERIVATIVES, THEIR PREPARATION, AND THEIR USE AS ANTIINFLAMATORY AGENT | AVENTIS PHARMA GMBH (DE) | 2005-04-20 | — | — | EP | disclosed |
| US-6680333-B2 | ANTIINFLAMMATORY AGENTS; RHEUMATIC DISEASES; ANTIALLERGENS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-01-20 | — | — | US | disclosed |
| EP-1373249-A1 | IMIDAZOLIDINE DERIVATIVES, THEIR PREPARATION, AND THEIR USE AS ANTINFLAMATORY AGENT | Aventis Pharma Deutschland GmbH (DE) | 2004-01-02 | — | — | EP | disclosed |
| US-20030073723-A1 | Novel imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-04-17 | — | — | US | disclosed |
| WO-2002072573-A1 | IMIDAZOLIDINE DERIVATIVES, THEIR PREPARATION, AND THEIR USE AS ANTINFLAMATORY AGENT. | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073723-A1 | Novel imidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them | VCAM1, ITGA4, ITGA1 | ITGB1 10/4885ITGA4 2/4885ITGB7 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.